← All trials
NCT06931717
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Mar 31, 2029
- Completion date
- Mar 31, 2029
- First posted
- Apr 17, 2025
- Last posted
- Nov 18, 2025
- Enrollment
- 390
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ETOP IBCSG Partners FoundationLead sponsor
- National University of SingaporeOfficial
- RegeneronCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.